Table 2: Visual and anatomic outcomes following bevacizumab injection.

PRN group ( )Three monthly initial dose group ( )

Visual improvement at month 6 (%)44 (63.8%)17 (65.4%)0.89
Complete resolution at month 6 (%)40 (58.0%)13 (50.0%)0.50
Recurrence over 6-month period (%)42 (60.9%)12 (46.2%)0.20
Absorption of retinal hemorrhage
 Month 3, % 0.027
 Month 6, % 0.41
Change of nonperfusion area
 Month 3, % 0.46
 Month 6, % 0.50

values were obtained by Student’s -test for continuous variables and chi-square test for dichotomous variables.
Percentages were calculated by dividing the area of hemorrhage absorption or change in nonperfusion areas by the area of the circle with a radius of 3600  m.
Negative numbers indicate the decrease in the area of nonperfusion during the time period.
Boldface indicates statistical significance ( ).